J.P. Morgan is out with its report today on Medivation MDVN, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "Our December 2011 price target of $12 is based on our probability-adjusted NPV analysis of MDV3100 and net cash. We assume a 20% probability of success for MDV 3100 discounted at 15%, which, based on our analysis, implies a value of roughly $5/share. Adding cash of $7/share, we believe $12/share is a reasonable estimate, which in turn justifies our Neutral rating."
Shares of MDVN closed Wednesday at $16.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.